NCT02205203 is a NA clinical trial of Mayo Clinic Anxiety Coach in Anxiety, sponsored by Stephen Whiteside.

Who is sponsoring NCT02205203?

NCT02205203 is sponsored by Stephen Whiteside.

What drugs are being tested in NCT02205203?

Interventions in NCT02205203: Mayo Clinic Anxiety Coach, Treatment as Usual.

Is NCT02205203 still recruiting?

NCT02205203 is currently completed. Last updated 29 March 2021.

Last reviewed 2021-03-29 · How we verify

NCT02205203

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Youth Mayo Clinic Anxiety Coach Randomized Controlled Trial

Completed NA Last updated 29 March 2021

What this trial tests

NA trial testing Mayo Clinic Anxiety Coach in Anxiety in 145 participants. Completed in 1 March 2021.

Timeline

1 January 2019

Primary endpoint
1 June 2020

1 March 2021

Quick facts

Lead sponsor	Stephen Whiteside
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	145
Start date	1 January 2019
Primary completion	1 June 2020
Estimated completion	1 March 2021
Sites	1 location across United States

Drugs / interventions tested

Mayo Clinic Anxiety Coach
Treatment as Usual

Conditions studied

Anxiety — all drugs for Anxiety →

Sponsor

Stephen Whiteside

Who can join

Adults 7 to 17, any sex, with Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study aims to test the feasibility and effectiveness of using the Mayo Clinic Anxiety Coach smartphone app as an addition to traditional therapy for the treatment of anxiety disorders in youth, particularly those youth who may have limited access to mental health treatment in the traditional clinical setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Using session recordings to understand the content of community-based treatment for childhood anxiety disorders and response to technology-based training.
Whiteside SPH, Sawchuk NR, Brennan E, Lebow JR, et al · · 2023 · cited 6× · PMID 37209422 · DOI 10.1002/jclp.23537

Verify or expand the search:

Other recruiting trials for Anxiety

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT07425951 — Building Cognitive Behavioural Skills With StoryBooks to Reduce Emotional Difficulties in Kindergarten Years · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02205203 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stephen Whiteside
Last refreshed: 29 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02205203.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing